The objectives of the study were to determine and categorize total serum PSA of treatment-naïve prostate cancer patients and correlate the PSA categories (0-4, 4.1-10, 10.1-20, 20.1-100, >100 ng/mL) with bone scan results. This evidence concerns the gene KLK3 and prostate cancer.